Sarcopenia in lung cancer: Could chest imaging help?

Jennifer Baima
University of Massachusetts Medical School

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/ortho_pp

Part of the Neoplasms Commons, Oncology Commons, Orthopedics Commons, Pathological Conditions, Signs and Symptoms Commons, Radiation Medicine Commons, Radiology Commons, and the Rehabilitation and Therapy Commons

Repository Citation

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Orthopedics and Physical Rehabilitation Publications and Presentations by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
There was no significant decrease in cross sectional area of the pectoralis in post-surgical patients over a one year lung cancer treatment period.

**INTRODUCTION**

- Analysis of iliopsoas cross-sectional area, a non-invasive surrogate measure for sarcopenia in patients with cancer has been associated with survival.
- More accessible in thoracic cancer, could measuring the cross-sectional area of the pectoralis be as accurate?

**METHOD**

- N=44 (13 had a complete set of imaging)
- 12/13 stage 1 or 2 and had undergone lobectomy
- 10/13 were ECOG performance grade 0 at diagnosis

**RESULTS**

- The mean iliopsoas area at diagnosis was 8.17cm². The mean pectoralis area at diagnosis was 14.5cm².
- 8 out of 13 subjects had a decrease in mean pectoralis area over 6 months and 6 subjects had a decrease at 12 months. These results were not statistically significant.

**DISCUSSION**

This could be because of the initial high performance status of our sample, the small size, or sarcopenia occurs comorbidly with presentation.